Role of gemcitabine in the treatment of ovarian cancer

Women's Health

Volumn 3, Issue 3, 2007, Pages 279-290

  AbuShahin, Fadi ^a   Rose, Peter G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Carboplatin; Cisplatin; Gemcitabine; Ovarian cancer; Paclitaxel; Recurrent ovarian cancer

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TOPOTECAN;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; EDEMA; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HAND FOOT SYNDROME; HUMAN; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TUMOR CELL DESTRUCTION;

EID: 34248647632     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.3.3.279     Document Type: Review

References (74)

1. du Bois A, Luck HJ, Meier W et al.: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst. 95(17), 1320-1329 (2003).
2. Ozols RF, Bundy BN, Greer BE et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin. Oncol. 21(17), 3194-3200 (2003).
3. Markman M, Rothman R, Hakes T et al.: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9(3), 389-393 (1991).
4. Gore ME, Fryatt I, Wiltshaw E, Dawson T: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36(2), 207-211 (1990).
5. Ozols RF, Ostchega Y, Curt G, Young RC: High-dose carboplatin in refractory ovarian cancer patients. J. Clin. Oncol. 5(2), 197-201 (1987).
6. Canetta R, Bragman K, Smaldone L, Rozencweig M: Carboplatin: current status and future prospects. Cancer Treat. Rev. 15(Suppl. B), 17-32 (1988).
7. Eisenhauer EA, Vermorken JB, van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8(10), 963-968 (1997).
8. van Moorsel CJ, Peters GJ, Pinedo HM: Gemcitabine: Future prospects of single-agent and combination studies. Oncologist 2(3), 127-134 (1997).
9. Heinemann V, Xu YZ, Chubb S et al.: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res. 52(3), 533-539 (1992).
10. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51(22), 6110-6117 (1991).
11. Gemzar® (for injection) prescribing information. Eli Lilly and Company, IN, USA (2006).
12. van Moorsel CJ, Pinedo HM, Veerman G et al.: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer 80(7), 981-990 (1999).
13. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22(4 Suppl. 11), 72-79 (1995).
14. Peters GJ, Van Moorsel CJ, Lakerveld B et al.: Effects of gemcitabine on cisplatinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int. J Oncol. 28(1), 237-244 (2006).
15. Moufarij MA, Phillips DR, Cullinane C: Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol. Pharmacol. 63(4), 862-869 (2003).
16. Yang LY, Li L, Jiang H, Shen Y, Plunkett W: Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin. Cancer Res. 6(3), 773-781 (2000).
17. Villella J, Marchetti D, Odunsi K, Rodabaugh K, Driscoll DL, Lele S: Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 95(3), 539-545 (2004).
18. Lund B, Hansen OP, Neijt JP, Theilade K, Hansen M: Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anti-Cancer Drugs 6(Suppl 6), 61-62 (1995).
19. Shapiro JD, Millward MJ, Rischin D et al.: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63(1), 89-93 (1996).
20. Friedlander M, Millward MJ, Bell D et al.: A Phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oncol. 9(12), 1343-1345 (1998).
21. Silver DF, Piver MS: Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am. J Clin. Oncol. 22(5), 450-452 (1999).
22. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP: Phase II study of gemcitabine in ovarian cancer. Ann. Oncol. 10(7), 853-855 (1999).
23. D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I: Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 88(3), 266-269 (2003).
24. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J: Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol. Oncol. 90(3), 593-596 (2003).
25. Bilgin T, Ozalp S, Yalcin OT, Zorlu G, Vardar MA, Ozerkan K: Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients. Eur. J. Gynaecol. Oncol. 24(2), 169-170 (2003).
26. Penson RT, Campos SM, Seiden MV et al.: A Phase II study of fixed dose rate gemcitabine in patients with relapsed mullerian tumors. Int. J. Gynecol. Cancer 15(6), 1035-1041 (2005).
27. Bookman MA, Malmstrom H, Bolis G et al.: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin. Oncol. 16(10), 3345-3352 (1998).
28. Hoskins P, Eisenhauer E, Beare S et al.: Randomized Phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 16(6), 2233-2237 (1998).
29. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19(14), 3312-3322 (2001).
30. Muggia FM, Hainsworth JD, Jeffers S et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15(3), 987-993 (1997).
31. Mutch D, Orlando M, Teneriello M et al.: Randomized Phase III trial of gemcitabine (Gem) versus pegylated liposomal doxorubicin (PLDox) for patients (pts) with platinum-resistant (Pt-R) taxane (tax)-pretreated ovarian cancer (OC) as 2nd or 3rd line chemotherapy. Gynecol. Oncol. 101 (Suppl. 2), 14 (2006).
32. du Bois A, Luck HJ, Pfisterer J et al.: Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann. Oncol. 12(8), 1115-1120 (2001).
33. Kose MF, Sufliarsky J, Beslija S et al.: A Phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecol. Oncol. 96(2), 374-380 (2005).
34. Papadimitriou CA, Fountzilas G, Aravantinos G et al.: Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol. Oncol. 92(1), 152-159 (2004).
35. Pfisterer J, Plante M, Vergote I et al.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24(29), 4699-4707 (2006).
36. Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M: Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol. Oncol. 88(1), 17-21 (2003).
37. Nagourney RA, Brewer CA, Radecki S et al.: Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol. Oncol. 88(1), 35-39 (2003).
38. Tewari D, Monk BJ, Hunter M, Falkner CA, Burger RA: Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest. New Drugs 22(4), 475-480 (2004).
39. Brewer CA, Blessing JA, Nagourney RA, Morgan M, Hanjani P: Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a Phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 103(2), 446-450 (2006).
40. Rose PG: Differential response to gemcitabine and platinum combinations in patients with inherent and acquired platinum-resistant ovarian and peritoneal carcinoma Gynecol. Oncol. 104(3S), 42 (2007).
41. Bozas G, Bamias A, Koutsoukou V et al.: Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Geynecol. Oncol. 104(3), 580-585 (2007).
42. Lehoczky O, Pulay T: [Experience with gemcitabine-carboplatin chemotherapy in relapsed ovarian cancer]. Orv. Hetil. 147(30), 1405-1408 (2006).
43. Sui M, Xiong X, Kraft AS, Fan W: Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol. Ther. 5(8), 1015-1021 (2006).
44. Iaffaioli RV, Tortoriello A, Santangelo M et al.: Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer. Clin. Oncol. (R. Coll. Radiol.) 12(4), 251-255 (2000).
45. Poole CJ, Perren T, Gawande S et al.: Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a Phase I trial in patients with recurrent ovarian cancer. Int. J. Gynecol. Cancer 16(2), 507-514 (2006).
46. Garcia AA, O'Meara A, Bahador A et al.: Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol. Oncol. 93(2), 493-498 (2004).
47. Gallo D, Fruscella E, Ferlini C, Apollonio P, Mancuso S, Scambia G: Preclinical in vivo activity of a combination gemcitabine/ liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP). Int. J Gynecol. Cancer 16(1), 222-230 (2006).
48. D'Agostino G, Ferrandina G, Garganese G et al.: Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology 62(2), 110-114 (2002).
49. Goff BA, Thompson T, Greer BE, Jacobs A, Storer B: Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A Phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602). Am. J. Obstet. Gynecol. 188(6), 1556-1562 (2003).
50. Skarlos DV, Kalofonos HP, Fountzilas G et al.: Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG Phase II study. Anticancer Res. 25(4), 3103-3108 (2005).
51. Ferrandina G, Paris I, Ludovisi M et al.: Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol. Oncol. 98(2), 267-273 (2005).
52. Petru E, Angleitner-Boubenizek L, Reinthaller A et al.: Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a Phase II Austrian AGO study. Gynecol. Oncol. 102(2), 226-229 (2006).
53. Greggi S, Salerno MG, D'Agostino G et al.: Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology 60(1), 19-23 (2001).
54. Sehouli J, Stengel D, Oskay G et al.: A Phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann. Oncol. 13(11), 1749-1755 (2002).
55. Chen MD. Fleming GF, Mitchell S. Horowitz I: A Phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 100(1), 111-115 (2006).
56. Hansen SW: Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin. Oncol. 29(1 Suppl. 1), 17-19 (2002).
57. Liu FS, Ho ES, Hung MJ, Hwang SF, Lu CH, Ke YM: Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan. Gynecol. Oncol. 94(2), 393-397 (2004).
58. Underhill CR, Parnis FX, Highley MS et al.: Multicenter Phase II study ofgemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anti-Cancer Drugs 12(8), 647-652 (2001).
59. Look KY, Bookman MA, Schol J, Herzog TJ, Rocereto T, Vinters J: Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 92(1), 93-100 (2004).
60. Nogue M. Cirera L, Arcusa A et al.: Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anti Cancer Drugs 13(8), 839-845 (2002).
61. Belpomme D, Krakowski I, Beauduin M et al.: Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a Phase II study. Gynecol. Oncol. 91(1), 32-38 (2003).
62. Harries M, Moss C, Perren T et al.: A Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br. J. Cancer 91(4), 627-632 (2004).
63. Micha JP, Goldstein BH, Rettenmaier MA et al.: Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol. Oncol. 94 (3), 719-724 (2004).
64. du Bois A, Belau A, Wagner U et al.: A Phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecol. Oncol. 96(2), 444-451 (2005).
65. Gupta SK, John S, Naik R et al.: A multicenter Phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaive advanced ovarian cancer. Gynecol. Oncol. 98(1), 134-140 (2005).
66. Fuso L, Amant F, Neven P, Berteloot P, Vergote I: Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution Phase II study in 24 patients. Int. J. Gynecol. Cancer 16(Suppl. 1), 60-67 (2006).
67. Hensley ML, Correa DD, Thaler H et al.: Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol. Oncol. 102(2), 270-277 (2006).
68. Gallardo D, Calderillo G, Serrano A et al.: A Phase II study of gemcitabine plus cisplatin in previously untreated advanced ovarian cancer. Anticancer Res. 26(4B), 3137-3141 (2006).
69. Tay S, Ilanchadran A, Tan T: First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a Phase II study. Br. J. Obstet. Gynaecol. 113(12), 1388-1392 (2006).
70. Maenpaa JU, Grenman SE, Jalkanen JT et al.: Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A Phase II study. Gynecol. Oncol. 101(1), 114-119 (2006).
71. Steer CB, Chrystal K, Cheong KA et al.: Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A Phase II trial of sequential doublets. The GO-First Study. Gynecol. Oncol. 103(2), 439-445 (2006).
72. Bookman M: GOG0182-ICON5: 5-arm Phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine, (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J. Clin. Oncol. ASCO Annual Meeting Proceedings 24(18S) (2006) (Abstract 5002).
73. du Bois A, Sehouli J, Lund B et al.: Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter Phase II study (AGO-OVAR 8) followed by a prospectively randomized Phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC. Int. J. Gynecol. Cancer 15 (S3), 224-225 (2005).
74. Parmar MK, Ledermann JA, Colombo N et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet 361(9375), 2099-2106 (2003).